Press Releases and Product Information July 13, 2022
advertisement
- Artificial pancreas app delivers stronger control of Type 1 diabetes in toddlers and young children in Cambridge study
- Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes
- Mylan Pharmaceuticals Inc., a Viatris Company, Issues Voluntary Nationwide Recall of One Batch of Insulin Glargine (Insulin glargine-yfgn) Injection Pens, 100 units/mL (U-100), Due to the Potential of Missing Labels on Some Pens
- Tubeless Insulin Pump Market to Reach USD 6,027 Million by 2030 Fueled by Increasing Incidence of Diabetes and Related Disorders